2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Fallopian Tube Neoplasms
14
Ovarian Neoplasms
12
Carcinoma, Ovarian Epithelial
8
Neoplasms
4
Triple Negative Breast Neoplasms
3
Endometrial Neoplasms
3
Breast Neoplasms
2
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
1
Interventions
mirvetuximab soravtansine
1
liposomal doxorubicin
1
Paclitaxel
1
Gemcitabine
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
×
mirvetuximab soravtansine
×
Clear all
NCT04274426
2026-05-13
MIROVA
AGO Research GmbH
Phase 2
Active not recruiting
136 enrolled